pravastatin has been researched along with pf-04991532 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiello, R; Ammirati, M; Aspnes, G; Atkinson, K; Baker, L; Barucci, N; Bian, J; Bourassa, P; Bourbonais, F; Cabrera, O; Chen, J; D'Aquila, T; Dasilva-Jardine, P; Derksen, DR; Duignan, DB; El-Kattan, A; Feng, B; Filipski, KJ; Guzman-Perez, A; Haddish-Berhane, N; Jones, CS; Knafels, J; Kosa, RE; Landro, JA; Lapworth, AL; Liras, S; Litchfield, J; Liu, S; Macdougall, M; Minich, ML; Murdande, S; Pettersen, J; Pfefferkorn, JA; Risley, H; Robertson, AS; Rolph, TP; Stevens, BD; Sweet, L; Tan, B; Treadway, JL; Tu, M; Varma, MV; Yao, L; Zavadoski, WJ | 1 |
1 other study(ies) available for pravastatin and pf-04991532
| Article | Year |
|---|---|
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Topics: Allosteric Site; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Enzyme Activators; Glucokinase; Haplorhini; Hepatocytes; Humans; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin-Secreting Cells; Male; Models, Molecular; Nicotinic Acids; Organic Anion Transporters; Protein Binding; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution | 2012 |